“…A number of sulfur-and nitrogen-containing heterocyclic compounds have been well studied. These molecules exhibit a wide range of biological applications, indicating that the 1,4benzothiazine moiety is a potentially useful template in medicinal chemistry research with therapeutic applications in the antimicrobial (Armenise et al, 2012, Sabatini et al, 2008, anti-viral (Malagu et al, 1998), anti-oxidant (Zia-ur-Rehman et al 2009), anti-inflammatory (Trapani et al, 1985;Gowda et al, 2011) antipyretic (Warren et al, 1987), and anti-cancer (Gupta et al, 1991;Gupta et al, 1985) areas as well as being precursors for the synthesis of new compounds (Sebbar et al, 2015a;Vidal et al, 2006) possessing anti-diabetic (Tawada et al, 1990) and anti-corrosion activities (Ellouz et al, 2016a,b; Sebbar et al, 2016a) and biological properties (Hni et al, ISSN 2056-9890 2019a; Ellouz et al, 2017aEllouz et al, ,b, 2018Sebbar et al, 2019a,b). As a continuation of our research into the development of new 1,4benzothiazine derivatives with potential pharmacological applications, we have studied the reaction of 1-bromononane with (Z)-2-(2,4-dichlorobenzylidene)-2H-1,4-benzothiazin-3(4H)-one under phase-transfer catalysis conditions using tetra-n-butylammonium bromide (TBAB) as catalyst and potassium carbonate as base (Hni et al, 2019b;Sebbar et al, 2019) to give the title compound, (I), in good yield.…”